The season, avian and swine flu strains are developing a resistance to Roche's anti-viral Tamiflu. Here are the possible reasons why:
http://www.sciencedaily.com/releases/2007/10/071002213442.htm
GSK's Relenza has to be inhaled, so cannot be administered to intubated, critically severe cases.
Hence, BCRX's Peramivir may play a leading role, as late-stage clinical trials in Japan and the US show positive results when administered intravenously.
Thursday, July 23, 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment